FI70012C - Foerfarande foer framstaellning av terapeutiskt anvaendbara 6-etoxi-2-acetylnaftalenoximderivat - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara 6-etoxi-2-acetylnaftalenoximderivat Download PDFInfo
- Publication number
- FI70012C FI70012C FI792414A FI792414A FI70012C FI 70012 C FI70012 C FI 70012C FI 792414 A FI792414 A FI 792414A FI 792414 A FI792414 A FI 792414A FI 70012 C FI70012 C FI 70012C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- methoxy
- therapeutic
- derivatives
- iii
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 239000002253 acid Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- FKUMAWUBPURONA-UHFFFAOYSA-N n-[1-(6-methoxynaphthalen-2-yl)ethylidene]hydroxylamine Chemical class C1=C(C(C)=NO)C=CC2=CC(OC)=CC=C21 FKUMAWUBPURONA-UHFFFAOYSA-N 0.000 claims description 5
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- GGWCZBGAIGGTDA-UHFFFAOYSA-N 1-(6-methoxynaphthalen-2-yl)ethanone Chemical compound C1=C(C(C)=O)C=CC2=CC(OC)=CC=C21 GGWCZBGAIGGTDA-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- -1 alkyl radical Chemical class 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUWMQEUWBPJTNQ-UHFFFAOYSA-N 1-(6-methoxynaphthalen-2-yl)-n-(2-pyrrolidin-1-ylethoxy)ethanimine;hydrochloride Chemical compound Cl.C1=CC2=CC(OC)=CC=C2C=C1C(C)=NOCCN1CCCC1 GUWMQEUWBPJTNQ-UHFFFAOYSA-N 0.000 description 2
- BJKZQNPIHGBLIV-UHFFFAOYSA-N 2-[1-(6-methoxynaphthalen-2-yl)ethylideneamino]oxy-n,n-dimethylethanamine Chemical compound C1=C(C(C)=NOCCN(C)C)C=CC2=CC(OC)=CC=C21 BJKZQNPIHGBLIV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CWKVFRNCODQPDB-UHFFFAOYSA-N 1-(2-aminoethylamino)propan-2-ol Chemical compound CC(O)CNCCN CWKVFRNCODQPDB-UHFFFAOYSA-N 0.000 description 1
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical class NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001539019 Monolene Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ZEHGKSPCAMLJDC-UHFFFAOYSA-M acetylcholine bromide Chemical compound [Br-].CC(=O)OCC[N+](C)(C)C ZEHGKSPCAMLJDC-UHFFFAOYSA-M 0.000 description 1
- 229940080018 acetylcholine injection Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7822836 | 1978-08-02 | ||
| FR7822836A FR2432506A1 (fr) | 1978-08-02 | 1978-08-02 | Nouveaux derives de 6-methoxy-2-acetylnaphtalene oxime, leur preparation et leur application en tant que medicaments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI792414A7 FI792414A7 (fi) | 1980-02-03 |
| FI70012B FI70012B (fi) | 1986-01-31 |
| FI70012C true FI70012C (fi) | 1986-09-12 |
Family
ID=9211492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI792414A FI70012C (fi) | 1978-08-02 | 1979-08-02 | Foerfarande foer framstaellning av terapeutiskt anvaendbara 6-etoxi-2-acetylnaftalenoximderivat |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4267334A (en, 2012) |
| JP (1) | JPS5555155A (en, 2012) |
| AR (1) | AR221502A1 (en, 2012) |
| AT (1) | AT367744B (en, 2012) |
| BE (1) | BE878019A (en, 2012) |
| BG (1) | BG36198A3 (en, 2012) |
| CA (1) | CA1128519A (en, 2012) |
| CH (1) | CH641773A5 (en, 2012) |
| CS (1) | CS215016B2 (en, 2012) |
| DD (1) | DD145266A5 (en, 2012) |
| DE (1) | DE2931319A1 (en, 2012) |
| EG (1) | EG14368A (en, 2012) |
| ES (1) | ES481855A1 (en, 2012) |
| FI (1) | FI70012C (en, 2012) |
| FR (1) | FR2432506A1 (en, 2012) |
| GB (1) | GB2045743B (en, 2012) |
| GR (1) | GR69826B (en, 2012) |
| IL (1) | IL57931A (en, 2012) |
| NL (1) | NL7905939A (en, 2012) |
| PL (1) | PL116462B1 (en, 2012) |
| PT (1) | PT70005A (en, 2012) |
| RO (1) | RO77339A (en, 2012) |
| SE (1) | SE446530B (en, 2012) |
| SU (1) | SU784763A3 (en, 2012) |
| YU (1) | YU41874B (en, 2012) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58156006U (ja) * | 1982-04-13 | 1983-10-18 | 日本電気ホームエレクトロニクス株式会社 | 車輌室内換気装置 |
| JPS61192912U (en, 2012) * | 1985-05-25 | 1986-12-01 | ||
| JPS63173814U (en, 2012) * | 1987-05-02 | 1988-11-11 | ||
| CN100575348C (zh) * | 2004-10-26 | 2009-12-30 | 西格玛-奥尔德利希公司 | 氨基酸n-羧酸酐的合成 |
| GB2435830A (en) * | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Oxime ether compounds for the treatment of conditions associated with food uptake |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3963778A (en) * | 1965-11-10 | 1976-06-15 | Bayer Aktiengesellschaft | Basic oximes and their preparation |
| US3937841A (en) * | 1967-04-05 | 1976-02-10 | U.S. Philips Corporation | Treatment of depression |
-
1978
- 1978-08-02 FR FR7822836A patent/FR2432506A1/fr active Granted
-
1979
- 1979-06-06 ES ES481855A patent/ES481855A1/es not_active Expired
- 1979-07-20 US US06/059,249 patent/US4267334A/en not_active Expired - Lifetime
- 1979-07-26 YU YU1821/79A patent/YU41874B/xx unknown
- 1979-07-30 DD DD79214687A patent/DD145266A5/de not_active IP Right Cessation
- 1979-07-31 PT PT70005A patent/PT70005A/pt unknown
- 1979-07-31 IL IL57931A patent/IL57931A/xx not_active IP Right Cessation
- 1979-07-31 GR GR59743A patent/GR69826B/el unknown
- 1979-07-31 CH CH705179A patent/CH641773A5/fr not_active IP Right Cessation
- 1979-08-01 PL PL1979217508A patent/PL116462B1/pl unknown
- 1979-08-01 NL NL7905939A patent/NL7905939A/nl not_active Application Discontinuation
- 1979-08-01 AT AT0528779A patent/AT367744B/de not_active IP Right Cessation
- 1979-08-01 CA CA333,015A patent/CA1128519A/fr not_active Expired
- 1979-08-01 SE SE7906509A patent/SE446530B/sv not_active IP Right Cessation
- 1979-08-01 EG EG466/79A patent/EG14368A/xx active
- 1979-08-01 JP JP9860079A patent/JPS5555155A/ja active Granted
- 1979-08-01 CS CS795313A patent/CS215016B2/cs unknown
- 1979-08-01 BG BG044522A patent/BG36198A3/xx unknown
- 1979-08-01 RO RO7998336A patent/RO77339A/ro unknown
- 1979-08-01 BE BE0/196559A patent/BE878019A/fr not_active IP Right Cessation
- 1979-08-01 DE DE19792931319 patent/DE2931319A1/de not_active Ceased
- 1979-08-02 FI FI792414A patent/FI70012C/fi not_active IP Right Cessation
- 1979-08-02 GB GB7926940A patent/GB2045743B/en not_active Expired
- 1979-08-02 SU SU792792753A patent/SU784763A3/ru active
- 1979-08-02 AR AR277580A patent/AR221502A1/es active
Also Published As
| Publication number | Publication date |
|---|---|
| GB2045743B (en) | 1982-09-02 |
| GB2045743A (en) | 1980-11-05 |
| AR221502A1 (es) | 1981-02-13 |
| JPS5555155A (en) | 1980-04-22 |
| NL7905939A (nl) | 1980-02-05 |
| JPS5748107B2 (en, 2012) | 1982-10-14 |
| BE878019A (fr) | 1980-02-01 |
| FR2432506B1 (en, 2012) | 1981-07-24 |
| CS215016B2 (en) | 1982-06-25 |
| FI792414A7 (fi) | 1980-02-03 |
| US4267334A (en) | 1981-05-12 |
| SU784763A3 (ru) | 1980-11-30 |
| AT367744B (de) | 1982-07-26 |
| PL217508A1 (en, 2012) | 1980-03-24 |
| EG14368A (en) | 1984-09-30 |
| SE446530B (sv) | 1986-09-22 |
| BG36198A3 (en) | 1984-09-14 |
| PL116462B1 (en) | 1981-06-30 |
| RO77339A (ro) | 1981-08-17 |
| DD145266A5 (de) | 1980-12-03 |
| FR2432506A1 (fr) | 1980-02-29 |
| IL57931A0 (en) | 1979-11-30 |
| IL57931A (en) | 1982-08-31 |
| YU41874B (en) | 1988-02-29 |
| SE7906509L (sv) | 1980-02-03 |
| YU182179A (en) | 1983-04-30 |
| CA1128519A (fr) | 1982-07-27 |
| PT70005A (fr) | 1979-08-01 |
| GR69826B (en, 2012) | 1982-07-13 |
| FI70012B (fi) | 1986-01-31 |
| DE2931319A1 (de) | 1980-02-14 |
| ATA528779A (de) | 1981-12-15 |
| CH641773A5 (fr) | 1984-03-15 |
| ES481855A1 (es) | 1980-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3637660A (en) | Dibenzazepine derivatives | |
| FI70012B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 6-etoxi-2-acetylnaftalenoximderivat | |
| SK143096A3 (en) | Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same | |
| US3764609A (en) | 1 (dibenzo {8 4,d{9 {0 cyclohepten-5-yl), 1-(dibenzo {8 a,d{9 {0 cycloheptan-5-yl) and 1-(dibenzo {8 a,d{9 {0 cyclooctanyl)imidazoles | |
| US5939555A (en) | Polymorphs B and C of 1- 2,4-dichloro-β- (7-chlorobenzo b!thien-3-yl)methoxy!phenethyl!imidazole mononitrate | |
| FI56966C (fi) | Foerfarande foer framstaellning av 2-(2-pyridyl)-omega-fenylalkylaminer med antisekretorisk aktivitet | |
| FI63566B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dibenso(d,g)(1,3,6)dioxazocin-derivat och av deras fysiologiskt godtagbara syraadditionssalter | |
| US3823155A (en) | Imidazoline derivatives with diuretic properties | |
| CA1077941A (en) | Piperidine derivatives of indole | |
| US3478056A (en) | 11-aminoalkylated dibenz(b,f) - 1,4-oxazepines and dibenzo-(b,f)-1,4-thiazepines | |
| GB2043060A (en) | 4-substituted 2-iminoimidazolidine compounds | |
| US3763153A (en) | Benzothiazines | |
| IL43298A (en) | Omega,omega-diphenyl-omega-imidazolyl-1-acetic acid amides,their production and pharmaceutical compositions containing them | |
| AU598663B2 (en) | Thiadiazole guanidines | |
| US3637702A (en) | 1-(hydroxyalkyl)-2-morpholinomethyl-5-nitroimidazoles | |
| JP2826838B2 (ja) | １−アリール−１−（１−シアノシクロプロパン−１−イル）−２−（１，２，４−トリアゾール−１−イル）エタノール誘導体またはその塩の製造法 | |
| US4035497A (en) | Butanoic and butenoic acid morpholides | |
| EP0248107B1 (en) | Thiophene ring-substituted alpha-(alkylaminopropionyl)-thiophene derivatives, a process for preparing them and pharmacuetical compositions containing them | |
| US4342763A (en) | P-Chloroacetophenone oxime compounds and pharmaceutical compositions | |
| US3418332A (en) | Dibenzocycloheptene thiazole derivatives | |
| FI69464C (fi) | Foerfarande foer framstaellning av farmakologiskt verksamma 10bromsandvicin och 10-bromisosandvicin | |
| FI72512B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbar 3-metyl-4-klor-5-(brometyl-aminometyl) isoxazol. | |
| US4093630A (en) | Diazabicycloalkane derivatives | |
| CS249111B2 (en) | Method of 1,2,4-oxadiazin's new derivatives production | |
| KR950002830B1 (ko) | 아미노알코홀 및 이를 함유하는 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: PROVESAN, S.A. |